Buy RTX on the Quadruple-Production Thesis: $205 Entry, $260 Target

Hook & thesis

RTX is a core defense prime with diversified aerospace exposure that stands to be a near-term beneficiary of an announced industry-wide push to quadruple munitions output. The market has already started to price in the story - RTX is trading near $205 after re-rating from earlier 2025 lows - but the scale of the manufacturing ramp and recurring aftermarket revenue still leave room for upside.

My trade: buy RTX at or near $205, set a stop at $188, and target $260 over a long term (180 trading days). The plan banks on accelerating orders for Raytheon Missiles & Defense (RMD) and follow-on engine wins at Pratt & Whitney to support both revenue and margin trajectory, and it keeps risk defined if the supply-side ramp or funding expectations falter.

Why the market should care

RTX operates four businesses that matter for this thesis: Collins Aerospace, Pratt & Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). RMD supplies end-to-end solutions to detect, track, and engage threats - precisely the product set a Pentagon supplemental would accelerate. Pratt & Whitney contributes engines used in tactical systems (recently supplying TJ150 turbojet engines for cruise missiles), which compounds revenue impact when both munitions and propulsion needs increase.

The backdrop has become catalytic. On 03/06/2026 the White House confirmed that major defense primes committed to quadrupling output of advanced weaponry. That public commitment accelerates capital spending and hiring at primes and their suppliers and increases near-term revenue visibility for companies with large backlogs. RTX already reports a large backlog and recurring aftermarket revenue streams - a structural advantage when raw procurement spikes.

Supporting numbers

Those numbers show two things. First, RTX is not cheap on traditional multiples - a ~41x P/E and EV/EBITDA north of 23 are consistent with premium defense/industrial growth expectations. Second, the company generates meaningful free cash flow - $7.94B - which provides ammunition for capex to expand factories, working capital to increase throughput, and steady shareholder returns (dividend yield ~1.33%). In this environment, investors are paying for both earnings growth and the optionality of capacity expansion.

Valuation frame

At a $274.5B market cap and $7.94B free cash flow, RTX trades at a FCF yield near 2.9% - low but not atypical for a large defense prime with steady government customers. A credible scenario where RMD and Pratt scale output, win follow-on supply contracts, and aftermarket revenue rises could drive both earnings growth and multiple expansion.

For perspective: moving the stock to $260 implies a ~19.5% price appreciation from $205 and a market cap approaching $348B. Given the current EV/EBITDA of 23.5x, even modest EBITDA growth from accelerated munitions production and better utilization could push the multiple higher if investors bid for growth and structural defense demand.

Catalysts

• Government supplemental appropriation or new procurement announcements that clarify funding for munitions production (near-term catalyst).
• Company-level contract awards and factory expansion announcements - e.g., Pratt & Whitney follow-on engine deals and new RMD production contracts (company-specific catalysts; note Pratt & Whitney secured a Leidos follow-on for TJ150 engines announced 03/10/2026).
• Quarterly results showing accelerating backlog conversion and margin improvement tied to higher mix of production rather than development (next 1-2 quarters).
• Signs of improved cash conversion and targeted capex that directly expand throughput at missile and engine facilities (operational catalyst over 3-6 months).

Trade plan

Entry: Buy RTX at $205.00.

Stop loss: $188.00. Execute stop if material evidence appears that funding will not materialize, or if broad risk-off market moves push industrials materially lower and sector leadership collapses.

Target: $260.00.

Horizon: long term (180 trading days). I expect this timeframe is sufficient for contract announcements, production ramps, and visible improvements in revenue/margins to be reflected in earnings and multiples.

Technical & market context

Technically, RTX is trading close to its short-term averages: the 20-day SMA is $204.32 and the 50-day SMA is $199.05, so the price sits near momentum support. RSI is neutral (~52) and short interest as of 02/27/2026 is modest relative to float (days-to-cover ~1.8), meaning moves can be orderly but can also accelerate if buyers step in on positive catalysts.

Risks and counterarguments

• Funding risk: The thesis depends on sustained government funding and a supplemental appropriation. If Congress limits spending or ties funds to other priorities, procurement timelines could slip.
• Execution risk: Quadrupling output is operationally hard - supplier bottlenecks, skilled labor constraints, and supply-chain delays could blunt revenue growth or pressure margins during the ramp.
• Price / multiple compression: RTX trades at elevated multiples (P/E ~41x, EV/EBITDA ~23.5x). If macro risk pushes valuation multiples lower, earnings improvements might not translate to higher share prices in the near-term.
• Geopolitical unpredictability: While conflict can accelerate procurement, it can also introduce volatility to defense contractors via changes in priority, export controls, or rapid shifts in strategy that favor other suppliers.
• Concentration of wins: A large portion of upside depends on RMD and Pratt & Whitney scaling. If new orders disproportionately favor other primes or smaller suppliers, RTX's share of incremental spending could be smaller than expected.

Counterargument

One strong counterargument is valuation: paying >40x earnings anticipates material growth and expanding margins. If the market doubts RTX's ability to convert backlog into higher margins quickly, investors could prefer cheaper alternatives like pure-play missile suppliers or other defense names whose multiples better reflect near-term earnings. In that scenario, even with higher sales, RTX might underperform peers on a relative basis.

Why I'm comfortable with the trade despite risks

RTX combines scale, diversified cash generation, and direct exposure to the most in-demand product sets (missiles and propulsion). The company already has a meaningful backlog and generates nearly $8B of free cash flow annually, which can fund factory expansion and working capital needs. The public commitment to quadruple output creates a higher baseline for demand assumptions, and the firm is positioned to capture follow-on supply chain spending.

What would change my mind

I would abandon the bullish stance if any of the following happens: (1) A credible congressional signal that supplemental funding will not be passed or will be materially cut; (2) Company updates that show major delays or cancellations in RMD/pratt production timelines; (3) A significant deterioration in cash flow or an earnings guide materially below consensus that points to structural margin issues unrelated to the ramp; (4) Broader market deleveraging that compresses multiples well below 20x for defense primes, removing the multiple-expansion centerpiece of the thesis.

Conclusion

RTX presents a defined, actionable trade to capture upside from an industry-wide production ramp. Entry at $205 with a $188 stop limits downside while a $260 target captures reasonable multiple expansion and the value of accelerated production and aftermarket revenues. This is a fundamentally driven trade that leans on cyclical demand, company-scale, and free cash flow strength - a pragmatic way to participate in defense upside while maintaining explicit risk controls.

Key near-term dates to watch

• Contract announcements and press releases (ongoing) - especially Pratt & Whitney and RMD wins (e.g., 03/10/2026 Pratt & Whitney follow-on engine deal announcement).
• Quarterly results that show backlog conversion and margin trajectory (next earnings cycle within ~1-2 quarters).

Trade at $205, stop $188, target $260 - time horizon: long term (180 trading days).